Loading...
XSWX
SANN
Market cap196mUSD
Dec 05, Last price  
12.20CHF
1D
0.99%
1Q
-14.33%
Jan 2017
-97.70%
IPO
-98.69%
Name

Santhera Pharmaceuticals Holding AG

Chart & Performance

D1W1MN
XSWX:SANN chart
P/E
—
P/S
4.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
59.58%
Rev. gr., 5y
-12.29%
Revenues
39m
-62.17%
781,0009,226,00048,0001,643,00020,609,0003,265,0003,538,0001,319,0002,591,0004,321,00019,033,00022,943,00031,657,00075,376,00015,008,000-1,595,0007,473,000103,414,00039,117,000
Net income
-42m
L
-28,258,000-27,871,000-44,656,00025,923,000-11,256,000-27,838,000-31,448,000-5,755,000-7,534,0005,949,000-35,415,000-51,532,000-54,186,000-18,973,000-67,659,000-55,526,000-71,076,00054,782,000-41,974,000
CFO
-36m
L
-24,833,000-22,371,000-45,691,000-20,753,000-6,636,000-19,894,000-11,039,000-6,976,000-6,063,000-22,390,000-27,137,000-39,633,000-37,865,0002,595,000-43,510,000-37,359,000-29,843,00047,271,000-35,527,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
URL
https://www.santhera.com/
IPO date
Nov 03, 2006
Employees
45
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT